
Haemonetics Announces Planned Offering of Convertible Senior Notes
Haemonetics Corporation has announced plans to offer $525 million in Convertible Senior Notes due 2029, subject to market conditions. This private offering will be made to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The company…













